Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Corporate & Fiscal
Pharmaceutical Events & Conferences
Terms & Conditions
With estimated prevalence levels of 3-10%, the treatment of Neuropathic Pain (NP) remains an area of significant unmet need. NP is highly individual in its presentation, level, underlying pathology and response to therapy. For some patients, available therapies give satisfactory pain control. For many others, treatments are poor or do not work at all. Therapeutic options include more than ten drug classes, which are commonly prescribed in combinations tailored to individual patient needs.
Interventional treatments, such as peripheral nerve block and transcutaneous electrical nerve stimulation, are also used as physicians seek other approaches to treating NP. This background, the individual nature of NP and the drug (or drug combination) options used to treat patients, has created a complex therapeutic picture.
In a therapeutic field where treatments are often unsatisfactory, physicians seek to extent their understanding of NP in an effort to define needs and limitations. Knowledge in these areas is also important to drug developers, who seek a better understanding of patient needs and outcomes, as part of their own efforts to develop more effective therapies. To meet interest in these areas, Biopharm Reports has conducted an in-depth global survey on current treatments and drug prescribing practices, relating to NP. This survey involved the participation of more than 330 physicians and clinical centres in 56 countries.
As part of this study, pain physicians were asked to described current limitations relating to the treatment of neuropathic pain. This report presents an analysis of these findings, provided by more than 300 study participants.
• Comprehensive details of current treatments for NP, provided by more than 330 clinics in 56 countries
• In-depth information relevant to markets and opportunities in the NP field
• 98% of participants are practicing physicians, working in specialised areas of pain treatment. Of these, 78% described themselves as specialists in pain treatment
• Leading participant countries were USA, Canada, UK, Australia, Denmark, France, Brazil, Germany, Netherlands and Belgium
• 74% of the clinical centres participating in this study were hospital pain departments, specialised pain practices or private pain clinics. Detailed information on the use of specific drug classes including tricyclic antidepressants, SSRIs, SNRIs, anticonvulsants, sodium channel blockers, opioids, NSAIDS, cannabinoids and Capsaicin
• Physicians have provided detailed feedback on the underlying pathologies associated with NP, seen in their patients
• Comprehensive information on the most frequently prescribed drugs from nine drugs classes, including drug combinations, for the treatment of NP. Biopharm Reports believes this provides the most comprehensive and up-to-date review and analysis in this area, currently available
• A detailed analysis of interventional methods used for the treatment of NP (e.g. peripheral nerve block, TENS)
• An assessment of average levels of pain relief achieved in the treatment of NP, in relation to 12 underlying conditions
• Informative views of participating physicians on current limitations, challenges and issues relating to the treatment of NP